Carlsmed AAQS
The The AAQS of Carlsmed (CARL) as of Oct 20, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
1
YoY
0.00%
Last updated:
Carlsmed has a current AAQS of 1.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Carlsmed in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Carlsmed in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Carlsmed AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2023
1.00 USD
Jan 1, 2024
1.00 USD
| YEAR | AAQS | YoY |
|---|---|---|
| 1 | 0.00% | |
| 1 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Carlsmed Stock analysis
What does Carlsmed do? Carlsmed, Inc. generates revenue through its aprevo technology platform, which provides AI-based solutions for the surgical workflow. The platform includes pre-operative AI-enabled planning software that uses diagnostic imaging and algorithms to create personalized surgical plans and design aprevo interbody implants. Intra-operative advanced visualization tools support precision placement of these implants, while post-operative data collection offers insights to refine future planning. The company targets medical professionals and hospitals in the United States, focusing on lumbar interbody fusion procedures. Its products are sold under the aprevo brand, with the platform available in the U.S. market for surgical planning and implant design.
Carlsmed's revenue streams come from the commercial sale of its aprevo technology platform, which integrates pre-operative planning, intra-operative visualization, and post-operative data analytics. The platform is specifically designed for lumbar interbody fusion procedures, addressing the needs of healthcare providers seeking to enhance surgical precision and outcomes. By leveraging AI-driven tools, Carlsmed enables personalized implant design and real-world data collection to improve surgical planning processes. The company's offerings are marketed to hospitals and surgeons in the U.S. healthcare sector, emphasizing the aprevo brand's role in digital surgical planning.
The aprevo technology platform serves as Carlsmed's core product, offering a comprehensive solution for surgical workflows. Its pre-operative software utilizes standard-of-care imaging and AI algorithms to develop patient-specific plans and implant designs. Intra-operative tools provide advanced visualization for precise implant placement, while post-operative data collection informs continuous improvement of the planning process. The platform is indicated for use in lumbar interbody fusion procedures and is commercially available in the United States, targeting healthcare institutions that prioritize AI-enhanced surgical planning and outcomes. Carlsmed is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Carlsmed stock
The AAQS of Carlsmed is 1 in 2024.
On Eulerpool you can find the complete historical development of The AAQS Carlsmed since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Carlsmed
All Key Metrics — Carlsmed
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth